A New IV Catheter Device Featuring Automatic and Integrated Blood Sampling

<strong>Technology</strong><br>

We offer a new IV catheter for the use during emergency and disasters to automatically preserve a pre-infusion blood sample from every patient.<br><br> The new catheter system is based on existing IV devices. Its new features include an integrated blood sampling reservoir that is fixed to the IV catheter via a flexible plastic band and remains attached to the patient following selffilling with a small blood volume until admission in the hospital. In addition, identifiers are provided comprising a housing identifier at the IV catheter and a reservoir identifier. Both identifiers have codes assigned to one another. The identifier system may comprise an electronic memory medium, in particular an RFID chip or barcode that can be read out. Upon arrival, the reservoir is disconnected from the patient and immediately sent to the laboratory for blood group typing. A prototype has been produced by injection molding process.<br><br> It has been demonstrated in a prospective phase II study that the device ensures rapid and precise blood typing in 100% of emergency patients showing that the new catheter design offered a significant advantage over the standard catheter. Furthermore, the new device increases patient safety by securing this precious very first blood sample in every case in addition to the sample taken from a central line inserted inside the hospital. Thereby two independently drawn specimens are available for ABO-typing even in circumstances with extreme time constraints.<br><br> <strong>Benefits</strong><br> <ul type=“disc“> <li>Increased patient safety</li> <li>Rapid and precise ABO typing</li> <li>Redundant patient to blood product identification for increased general transfusion safety</li> <li>No interference with routine procedures</li> <li>Prevention of excessive use of 0 negative blood resources, thus allowing further cost reduction</li> </ul> <p><strong>IP Rights</strong><br> DE102004055989B4 and DE102009018837B4 granted<br> EP and US patent pending <br> (Priority Nov 2004) <br><br> <strong>Patent Owner</strong><br> Charité – Universitätsmedizin Berlin

Weitere Informationen: PDF

ipal GmbH
Tel.: +49 (0)30/2125-4820

Ansprechpartner
Dr. Dirk Dantz